Kimmtrak (Tebentafusp)

Tebentafusp is a bispecific T‑cell engager that binds CD3 on a patient’s T‑cells and the gp100 peptide presented by HLA‑A*02:01 on melanoma cells. This dual binding redirects T‑cells to the tumor, activating them to release cytokines and directly lyse cancer cells.

The dosing regimen for Kimmtrak is determined by the prescribing oncologist based on the patient’s clinical status, body weight, and HLA‑A*02:01 positivity. Specific dose and infusion schedule are outlined in the product’s prescribing information.

Safety data for Kimmtrak in pregnant or breastfeeding individuals are limited. The product’s labeling advises that it should only be used if the potential benefit justifies any potential risk to the fetus or infant, and decisions should be made in consultation with a healthcare professional.

To request Kimmtrak, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain handling if needed), and required import documentation.

Kimmtrak is a bispecific T‑cell engager targeting gp100 peptide–HLA‑A*02:01 complexes, whereas many other melanoma immunotherapies, such as checkpoint inhibitors (e.g., pembrolizumab), act by releasing inhibitory pathways on T‑cells. Kimmtrak’s mechanism provides a direct, antigen‑specific redirection of T‑cells, offering an alternative for patients with HLA‑A*02:01‑positive uveal melanoma.

Kimmtrak must be stored refrigerated at 2‑8 °C. It should be kept in its original packaging, protected from light, and must not be frozen or shaken. Proper cold‑chain logistics are essential to maintain product stability until administration.

Kimmtrak is given as an intravenous infusion in a clinical setting. The infusion is performed by qualified healthcare personnel, with monitoring of vital signs and observation for infusion‑related reactions throughout the administration period.

The most serious adverse events include severe cytokine release syndrome, cardiac complications such as arrhythmia or myocarditis, neurotoxicity (e.g., seizures or confusion), and anaphylaxis. Prompt recognition and management of these reactions are critical during and after infusion.

Kimmtrak should not be used in patients who lack the HLA‑A*02:01 allele, have uncontrolled active infections, or have a history of severe hypersensitivity to the drug. Caution is also advised for pregnant or breastfeeding individuals and for patients with significant cardiac disease.